Non-survivor patients with malignant middle cerebral artery infarction showed persistently high serum malondialdehyde levels.
Leonardo LorenteMaría M MartínPedro Abreu-GonzálezRafael SabatelLuis RamosMónica ArguesoJordi Solé-ViolánJuan J CáceresAlejandro JiménezVictor García-MarínPublished in: BMC neurology (2019)
The new findings of our study were that serum malondialdehyde levels during the first week of MMCAI could be used as biomarkers to mortality prediction.